| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $842,151 ) |
| | 2024 | 2024 | SCARAB GENOMICS LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44GM156147 | An improved low-endotoxin Clean Genome E. coli strain for production of biological products | 001 | 1 | NIH | 9/24/2024 | $0 |
| | 2024 | 2024 | SCARAB GENOMICS LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44GM156147 | An improved low-endotoxin Clean Genome E. coli strain for production of biological products | 000 | 1 | NIH | 8/28/2024 | $842,151 |
| | 2024 | 2022 | SCARAB GENOMICS LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44AI155307 | Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture | 000 | 3 | NIH | 9/18/2024 | $0 |
| | 2024 | 2021 | SCARAB GENOMICS LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44AI094823 | Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain | 000 | 6 | NIH | 1/16/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2020 | SCARAB GENOMICS LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44AI143170 | Lysis-free extraction of biopharmaceuticals from the periplasm of Clean Genome E. coli | 000 | 3 | NIH | 8/24/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $961,744 ) |
| | 2022 | 2022 | SCARAB GENOMICS LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44AI155307 | Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture | 000 | 3 | NIH | 6/17/2022 | $961,744 |
| | 2022 | 2021 | SCARAB GENOMICS, LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44AI094823 | Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain | 000 | 6 | NIH | 3/1/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,982,648 ) |
| | 2021 | 2021 | SCARAB GENOMICS, LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44AI094823 | Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain | 000 | 6 | NIH | 2/10/2021 | $1,000,000 |
| | 2021 | 2021 | SCARAB GENOMICS, LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44AI155307 | Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture | 000 | 2 | NIH | 6/7/2021 | $944,508 |
| | 2021 | 2018 | SCARAB GENOMICS, LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44AI129149 | Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics? reduced genome E. coli strains | 001 | 3 | NIH | 11/24/2020 | $0 |
| | 2021 | 2017 | SCARAB GENOMICS, LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44AI129149 | Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics? reduced genome E. coli strains | 000 | 2 | NIH | 10/29/2020 | $38,140 |
|
| Issue Date FY: 2020 ( Subtotal = $2,737,950 ) |
| | 2020 | 2020 | SCARAB GENOMICS, LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44AI143170 | Lysis-free extraction of biopharmaceuticals from the periplasm of Clean Genome E. coli | 002 | 3 | NIH | 6/26/2020 | $737,950 |
| | 2020 | 2020 | SCARAB GENOMICS, LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44AI094823 | Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain | 000 | 5 | NIH | 2/14/2020 | $1,000,000 |
| | 2020 | 2020 | SCARAB GENOMICS, LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44AI155307 | Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture | 000 | 1 | NIH | 7/13/2020 | $1,000,000 |
| | 2020 | 2019 | SCARAB GENOMICS, LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44AI143170 | Lysis-free extraction of biopharmaceuticals from the periplasm of Clean Genome E. coli | 001 | 2 | NIH | 6/26/2020 | $0 |
| | 2020 | 2019 | SCARAB GENOMICS, LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44AI143170 | Lysis-free extraction of biopharmaceuticals from the periplasm of Clean Genome E. coli | 000 | 1 | NIH | 3/16/2020 | $0 |
| | 2020 | 2017 | SCARAB GENOMICS, LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44GM105177 | Characterization of a low mutation rate E. coli in extended fermentation | 000 | 3 | NIH | 11/16/2019 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $2,067,360 ) |
| | 2019 | 2019 | SCARAB GENOMICS, LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44AI143170 | Lysis-free extraction of biopharmaceuticals from the periplasm of Clean Genome E. coli | 002 | 2 | NIH | 9/13/2019 | $41,007 |
| | 2019 | 2019 | SCARAB GENOMICS, LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44AI143170 | Lysis-free extraction of biopharmaceuticals from the periplasm of Clean Genome E. coli | 000 | 1 | NIH | 12/12/2018 | $156,171 |
| | 2019 | 2019 | SCARAB GENOMICS, LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44AI143170 | Lysis-free extraction of biopharmaceuticals from the periplasm of Clean Genome E. coli | 001 | 2 | NIH | 6/20/2019 | $870,182 |
| | 2019 | 2019 | SCARAB GENOMICS, LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44AI094823 | Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain | 000 | 4 | NIH | 3/20/2019 | $1,000,000 |
|
| Issue Date FY: 2018 ( Subtotal = $732,197 ) |
| | 2018 | 2018 | SCARAB GENOMICS, LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44AI129149 | Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics? reduced genome E. coli strains | 001 | 3 | NIH | 6/29/2018 | $706,927 |
| | 2018 | 2017 | SCARAB GENOMICS, LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44AI129149 | Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics? reduced genome E. coli strains | 000 | 2 | NIH | 4/9/2018 | $25,270 |
|
| Issue Date FY: 2017 ( Subtotal = $1,832,673 ) |
| | 2017 | 2017 | SCARAB GENOMICS, LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44AI129149 | Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics? reduced genome E. coli strains | 001 | 1 | NIH | 6/7/2017 | -$38,140 |
| | 2017 | 2017 | SCARAB GENOMICS, LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44GM105177 | Characterization of a low mutation rate E. coli in extended fermentation | 000 | 3 | NIH | 6/6/2017 | $864,106 |
| | 2017 | 2017 | SCARAB GENOMICS, LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44AI129149 | Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics? reduced genome E. coli strains | 002 | 2 | NIH | 7/24/2017 | $852,485 |
| | 2017 | 2017 | SCARAB GENOMICS, LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44AI129149 | Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics? reduced genome E. coli strains | 000 | 1 | NIH | 12/14/2016 | $154,222 |
| | 2017 | 2015 | SCARAB GENOMICS, LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44AI094823 | Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain | 000 | 3 | NIH | 6/23/2017 | $0 |
| | 2017 | 2014 | SCARAB GENOMICS, LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44GM105183 | A protease-deficient, low mutation rate E. coli for biotherapeutics production | 000 | 3 | NIH | 11/15/2016 | -$95,979 |
| | 2017 | 2014 | SCARAB GENOMICS, LLC | 1202 ANN ST | MADISON | WI | 53713-2410 | DANE | USA | R44GM105183 | A protease-deficient, low mutation rate E. coli for biotherapeutics production | 001 | 3 | NIH | 2/14/2017 | $95,979 |
|
| Issue Date FY: 2016 ( Subtotal = $1,554,424 ) |
| | 2016 | 2016 | SCARAB GENOMICS LLC | 1202 ANN STREET | MADISON | WI | 53713-2410 | DANE | USA | R44GM105177 | Characterization of a low mutation rate E. coli in extended fermentation | 000 | 2 | NIH | 5/19/2016 | $1,554,424 |
|
| Issue Date FY: 2015 ( Subtotal = $728,655 ) |
| | 2015 | 2015 | SCARAB GENOMICS LLC | 1202 ANN STREET | MADISON | WI | 53713-2410 | DANE | USA | R44AI094823 | Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain | 000 | 3 | NIH | 3/17/2015 | $728,655 |
|
| Issue Date FY: 2014 ( Subtotal = $1,446,410 ) |
| | 2014 | 2014 | SCARAB GENOMICS LLC | 1202 ANN STREET | MADISON | WI | 53713-2410 | DANE | USA | R44AI094823 | Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain | 000 | 2 | NIH | 5/20/2014 | $732,955 |
| | 2014 | 2014 | SCARAB GENOMICS LLC | 1202 ANN STREET | MADISON | WI | 53713-2410 | DANE | USA | R44GM105183 | A protease-deficient, low mutation rate E. coli for biotherapeutics production | 000 | 3 | NIH | 7/28/2014 | $713,455 |
|
| Issue Date FY: 2013 ( Subtotal = $1,175,375 ) |
| | 2013 | 2013 | SCARAB GENOMICS LLC | 1202 ANN STREET | MADISON | WI | 53713-2410 | DANE | USA | R43GM105177 | CHARACTERIZATION OF A LOW MUTATION RATE E. COLI IN EXTENDED FERMENTATION | 000 | 1 | NIH | 4/29/2013 | $297,922 |
| | 2013 | 2013 | SCARAB GENOMICS LLC | 1202 ANN STREET | MADISON | WI | 53713-2410 | DANE | USA | R43GM105177 | CHARACTERIZATION OF A LOW MUTATION RATE E. COLI IN EXTENDED FERMENTATION | 001 | 1 | NIH | 8/20/2013 | -$15,304 |
| | 2013 | 2013 | SCARAB GENOMICS LLC | 1202 ANN STREET | MADISON | WI | 53713-2410 | DANE | USA | R44GM105183 | A protease-deficient, low mutation rate E. coli for biotherapeutics production | 001 | 2 | NIH | 8/28/2013 | $910,959 |
| | 2013 | 2012 | SCARAB GENOMICS LLC | 1202 ANN STREET | MADISON | WI | 53713-2410 | DANE | USA | R44GM105183 | A protease-deficient, low mutation rate E. coli for biotherapeutics production | 000 | 1 | NIH | 8/21/2013 | -$18,202 |
|
|
